Traws Pharma Financials

Traws Pharma (TRAW) reported $226K in total revenue for fiscal year 2024. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Traws Pharma (TRAW) revenue grew by 0% year-over-year, from $226K to $226K in fiscal year 2024.

No, Traws Pharma (TRAW) reported a net income of -$166.5M in fiscal year 2024, with a net profit margin of -73682.7%.

Traws Pharma (TRAW) reported diluted earnings per share of $-35.21 for fiscal year 2024. This represents a -56.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Traws Pharma (TRAW) had EBITDA of -$142.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

Traws Pharma (TRAW) had an operating margin of -62997.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

Traws Pharma (TRAW) had a net profit margin of -73682.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Traws Pharma (TRAW) generated -$33.4M in free cash flow during fiscal year 2024. This represents a -86.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Traws Pharma (TRAW) generated -$29.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Traws Pharma (TRAW) had $25.0M in total assets as of fiscal year 2024, including both current and long-term assets.

Traws Pharma (TRAW) invested $3.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Traws Pharma (TRAW) invested $12.8M in research and development during fiscal year 2024.

Traws Pharma (TRAW) had 4M shares outstanding as of fiscal year 2024.

Traws Pharma (TRAW) had a current ratio of 2.16 as of fiscal year 2024, which is generally considered healthy.

Traws Pharma (TRAW) had a debt-to-equity ratio of -1.79 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Traws Pharma (TRAW) had a return on assets of -667.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Traws Pharma (TRAW) has negative shareholder equity of -$31.6M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Traws Pharma (TRAW) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Traws Pharma (TRAW) has an earnings quality ratio of 0.18x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

Traws Pharma (TRAW) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.